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Summary Water suppressed proton nuclear magnetic resonance ('H NMR) spectroscopy of human plasma
has been described as successful in detection of malignancy. We designed a prospective study to test the
hypothesis that in vitro NMR spectroscopy has a high sensitivity for detecting early breast cancer. One
hundred and thirty-five women were referred for breast biopsy due to abnormal mammograms. One hundred
of these were recruited through a population-based mammography screening project. Sixty-nine of 135 women
were found to have breast cancer and their average line width of the methyl and methylene resonance in the
plasma were compared to those women who had a benign or normal histopathology in the biopsy and to the
line width for 100 healthy subjects from the same population. The mean line width at a half-height of the
methyl and methylene resonances of the serum lipoprotein lipids in the NMR spectrum did not differ
appreciably between the groups. The line width correlated highly with the serum triglycerides, but correction
for the level of triglycerides did not improve the diagnostic accuracy of the line width. Receiver-operating
characteristic analysis revealed a sensitivity of 61% and a false positive rate of 43% at the most beneficial
cut-off of line width (39.7 Hz). In vitro NMR spectroscopy in our hands was thus not a useful diagnostic tool
in patients with early breast cancer.
Fossel et al. have described the successful application of in
vitro water-suppressed proton nuclear magnetic resonance
('H NMR) spectroscopy of human plasma for the detection
of malignancy (1986). They reported a statistically signi-
ficantly narrower average line width of the methyl and
methylene resonance in the plasma of patients with cancer
than in healthy subjects. The water-suppressed proton spec-
trum of plasma contains resonances attributable to lipopro-
tein lipids. It is possible that a number of lipid alterations
described in patients with cancer may change the distribution
of low density and high density lipoproteins and thereby
influence the line shape of those signals (Mims et al., 1989).
However, Fossel's findings have never been fully supported
by other investigations and most studies have shown a con-
siderable overlap in the distribution of line widths between
individuals with and without cancer (Okunieff et al., 1990). A
strong correlation has also been found between the line width
and the serum triglyceride level (Mims et al., 1989; Okunieff
et al., 1990).
We designed a prospective study to test the hypothesis that
in vitro NMR spectroscopy has a high sensitivity for detect-
ing early breast cancer. Women with operable breast cancer
were compared to those who underwent a surgical breast
biopsy because of benign disease and a control group of 100
apparently healthy women. Samples were drawn simultan-
eously for measuring the mean value of the line widths of the
methyl and methylene signals as well as the serum trigly-
ceride levels. Serum triglyceride levels were adjusted for use
in the multivariate analyses.
Subjects and methods
Subjects
Women in one county of Sweden consecutively referred for
surgery because of abnormal mammographic findings were
asked to participate in the study (biopsy group). Women who
had had breast cancer or were being treated for any other
type of cancer or hematological disorder were excluded. A
total of 135 (96% of the eligible) subjects agreed to par-
ticipate and 69 of them were found to have breast cancer.
Thus the biopsy group was subdivided into one group with
malignant and another with benign or normal histological
findings. The sample size was predetermined to 120 by power
calculations. Our aim was to detect differences in line width
of the same magnitude as that described by Fossel, with 80%
power and a 5% significance level. One hundred of the
women were referred directly from a mammography screen-
ing center. The screening was a population-based public
health care program for mammography alone.
To obtain a reference group that was not subject to pre-
operative psychological stress, 100 healthy subjects from the
same population were enrolled from an ongoing population-
based screening study for primary hyperparathyroidism
among women 50 years of age and older. All these women
gave their informed consent.
Data collection
On the day before surgery the women in the biopsy group
were asked whether they had had a malignant tumour earlier
in life, whether they smoked, whether they were on a special
diet, when they had had their most recent meal and what it
consisted of. Blood samples for determinations of the line
width, serum triglycerides, serum cholesterol, serum FSH and
estradiol were then drawn. Data about source of referral,
histopathological diagnosis and tumour stage were obtained
from the medical records.
The healthy women were asked the same set of questions
as those in the biopsy group. At the same time as the blood
samples were drawn for the primary hyperparathyroidism
screening, a blood sample for line width, serum triglycerides
and serum cholesterol was drawn.
A second blood sample was taken from 20 of the 69
patients with breast cancer 3-4 months after completion of
therapy. These women had stage I or II cancer and were
considered to be free of disease at the time.
Laboratory methods
EDTA-prepared tubes were used for blood sampling. The
samples were centrifuged to obtain the plasma fraction
within 60 min. The plasma was kept in the refrigerator for
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1-6 days before the NMR measurement. The plasma sam-
ples were coded so that the NMR laboratory was blinded to
the women's disease status. No one at the NMR laboratory
had access to information from the hospital regarding the
study subject.
A Bruker AM 400 instrument ('H; 400 MHz) was used.
Each plasma sample of ca 0.5 ml was diluted with 0.15 ml
D20 (for locking). The probe temperature was adjusted to
21°C. Optimisation of the instrument was carried out accord-
ing to the protocol of Fossel et al. (1986). The water signal
was presaturated for 4 s prior to applying a 900 pulse or an
inversion/recovery sequence (Hartmann-Hahn) for obtaining
the spectrum. The latter technique was used to remove the
signals from all fast relaxing protons e.g., the peak from the
lactate protons which coincides with the methylene protons.
After processing, using a line-widening of 2 Hz, the spectra
were baseline-corrected using a spline function. The line
widths at half-height of the methylene and methyl signals
were then measured with a ruler. The size of the mean value
of these two line widths is a significant indication of the
presence of cancer, according to Fossel et al. (1986).
The processed data presented in this paper are extracted
from the inversion/recovery experiments. However, control
calculations of data from regular 90°-experiments lead to
similar results and the same conclusion.
Statistical analysis
The line widths of the patients with cancer, those with a
benign finding, and the healthy controls were compared by
linear regression. Correction for the triglyceride level and age
was made. In the biopsy group, the relation of the line width
to cancer status was further analysed, taking the following
co-variates into account: (a) in a continuous form - cho-
lesterol, serum FSH and estradiol, (b) as categorical variables
- source of referral (screening vs clinical), the use of any
special diet, ingestion of a fatty meal less than 2 h before
blood sampling, current smoking status and treatment for
other forms of cancer.
In order to relax the assumption of a pre-defined normal
range of line width, receiver-operating characteristic (ROC)
analysis (McNeil & Hanley, 1984; Swets, 1988) was used. The
ROC curves represent a plot of sensitivity vs the rate of false
positives (1 - specificity) and they can identify the cut-off
point where the line width can best distinguish the two
groups.
Results
The characteristics of the three groups of women are shown
in Table I. The age distribution was different in the three
groups, women with benign breast disease being the young-
est. The number of women who were currently smoking was
somewhat lower in the healthy subjects group. The levels of
triglycerides and cholesterol tended to vary in a way that
would be expected from the age distribution.
Of the women with cancer, 83% had a tumour less than
20 mm in diameter and only 20% had nodal involvement of
the axilla. Thirty percent of them had an undifferentiated
ductal cancer.
The average line width was only marginally smaller among
women with cancer than in those with benign breast disease
(Table II). The average line width was very similar among
the 100 healthy controls and the women with cancer. A
regression of the line width correcting for triglyceride level
and age, revealed no differences between the groups (Table
II).
In the biopsy group, the relationship between disease
status (cancer or benign), triglyceride level, age and line
width was analysed in greater detail (Table III). The trigly-
ceride level taken on its own correlated negatively with the
line width, which is also illustrated in Figure 1. With only
age in the model, age correlated weakly although significantly
with a smaller line width. However, when the disease status,
age and triglycerides were included in the model, the statis-
tical significance of age disappeared. Moreover, the indicator
term for disease status showed no tendency to become statis-
tically significant. When corrections were made for
cholesterol, source of referral, any type of special diet, the
intake of a fatty meal less than 2 h before blood sampling,
current smoking habits, serum FSH, serum estradiol (E2) and
cancer ealier in life (model 4 in Table III), the triglyceride
level remained statistically significant. The age parameter
estimate was not altered, but the parameter estimate for
cancer increased its numerical value, with a concomitant
proportional reduction in the standard error. This finding
implies that some of the factors in the model were negatively
confounding the relationship between the presence of cancer
and line width. However, the parameter estimate for presence
of cancer was still not significantly different from zero.
Among the 69 cancer cases, the possibility of correlations
between the line width and the size and type of the tumour
and nodal involvement were investigated (Table IV). After
Table I Demographic characteristics of the women with cancer and those with a
benign lesion in the biopsy group, and of the healthy controls
Women with
Women with benign lesion Healthy controls
cancer n = 69 n = 66 n = 100
Mean age (s.d.) years 60.8 (12.3) 54.2 (12.0) 66.4 (5.4)
Other cancer earlier in life 3 2 9
Current smoker 15 16 12
Special diet (vegetarian, 7 4 5
diabetes, etc)
Referred by screening center 50 50 _
Mean triglyc. mmol -' (s.d.) 1.9 (1.2) 1.5 (0.9) 2.0 (1.5)
Mean cholesterol, mmoll' (s.d.) 6.5 (1.4) 6.1 (1.4) 7.0 (1.3)
aNot applicable
Table II Mean (s.d.) line width (Hz), in the three groups. P-value refers to
P-value of parameter estimate for dummy variable representing group
allocation, including a correction for triglycerides and age. The healthy 100
women is the reference group
Biopsy = Biopsy = Health
cancer benign controls
Mean (s.d.) line width 34.4 (5.2) 36.2 (6.8) 34.2 (7.5)
P-value (regression of line width 0.85 0.61 Ref.
corrected for triglyc. + age)NMR IN EARLY BREAST CANCER 391
Table III Parameter estimates (s.e.) in regression models with a line width as the dependent
variable
Model 1 2 3 4
Triglyc -3.64 (0.38) - -3.73 (0.41) -3.31 (0.37)
Age (years) - -0.11 (0.04) 0.03 (0.04) -0.03 (0.04)
Cancer (present vs absent) - - -0.57 (0.87) - 1.19 (0.70)
R-square (adj) 0.43 0.04 0.44 0.60
Triglycerides and age analysed in continuous form. R-square was adjusted (adj) for the
number ofindependent variables in the model. Model 1 includes only triglycerides, model 2 only
age, model 3 includes both these factors plus disease status. Model 4 is also adjusted for:
cholesterol, referral basis, special diet, fatty meal before sampling, smoking, FSH, E2, earlier
cancer.
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Figure 1 Plot of line width vs level of serum triglycerides. Para-
meter estimate in regression equals - 3.64.
0.2 0.4 0.6 0.8
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1.0
Figure 2 Receiver-operating characteristic (ROC) curve: sensiti-
vity (% true positives) vs 1 - specificity (% false positives). The
maximum (sensitivity - percent false positives) is 17.5% at maxi-
mum sensitivity 61%, false positives 43% at line width = 39.67
H3.
correction for age and triglyceride level, no correlation was
found (Table IV). The ROC curves confirmed the impression
that the line width was not helpful as a diagnostic marker. At
the most beneficial cut point (line width = 39.7 Hz), the sen-
sitivity was as low as 61% and the percentage of false
positives was 43% (Figure 2).
The line width for the 20 women at the follow-up 3-4
months postoperatively was compared to their line widths
preoperatively. A regression correction for age and trigly-
cerides and a paired t-test confirmed that the differences were
very small and that the line width primarily depended on the
current level of serum triglycerides.
Discussion
We found no evidence that the mean line width at a half-
height of the methyl and methylene resonances of the serum
lipoprotein lipids in the NMR spectrum could be used to
distinguish women with cancer from healthy subjects or from
women with mammographical abnormalities due to benign
disease. The line width correlated highly with the level of
serum triclycerides. Correction for the level of triglycerides
Table IV Regression model for cancer cases with line width as the
dependent variable
Parameter
estimate (s.d.)
Tumour size (mm) 0.04 (0.08)
Tumour type (undifferentiated vs other) 0.37 (1.0)
Nodal status (nodal metastases present vs absent) 1.6 (1.2)
Models corrected for age and triglycerides in continuous form.
did not improve the diagnostic accuracy of the line
width.
The study design was rigorous and ideally suited to answer
the question whether in vitro NMR spectroscopy can detect
breast cancer in the preclinical stage. The study subjects
comprised a consecutive sample from a population-based
screening program. Almost all the patients with breast abnor-
malities were asymptomatic and the diagnosis of cancer in
these cases was not established until after the operation - i.e.,
after the blood samples were drawn. Thus the patient's diag-
nosis was blind in relation not only to the NMR analysis but
also to the person who drew the blood samples and took the
history. We were able to adjust for the serum triglyceride
level in every individual.
According to our results, NMR line width has virtually no
power to detect early breast cancer. Although no one has
systematically studied the domain of preclinical breast
cancer, our results agree with those of several other investi-
gators (Bell et al., 1987; Nicholson & Nicholson, 1987; Small
& Hamilton, 1987; Buchthal et al., 1988; Berger et al., 1989;
Herring et al., 1989; Engan et al., 1990; Otvos et al., 1991).
No other study has included unselected controls from the
same source population as the cases. Similar results which
show that ROC analysis is of little diagnostic value have also
been obtained by others (Otvos et al., 1991). Two further
reports (Peeling et al., 1988; Hofeler & Scheulen, 1989) credit
in vitro NMR spectroscopy with a greater capacity to detect
cancer but they still found a considerable overlap between
the various patient groups (Peeling et al., 1988), and inconsis-
tent results when the experiment was repeated (Hofeler &
Scheulen, 1989). They did not determine the serum trig-
lyceride levels (Peeling et al., 1988; Hofeler & Scheulen,
1989).
We followed Fossel's laboratory methods carefully. The
lack of a difference in line width in our investigation may be
due to a low 'tumour burden' among the patients with
..
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cancer. This possibility is partially offset by the lack of
correlation between a preoperative tumour burden and line
width and by the lack of a significant change after removal of
the primary tumour. Moreover, if the size of the breast
cancer must be appreciably larger than in this study to be
detected by NMR, this method would have little clinical
value. The use of line width for distinguishing between
benign and malignant disease would then fall short of other
methods, such as mammography, cytology and clinical inves-
tigation.
In summary in vitro NMR spectroscopy in our hands was
not a useful diagnostic tool in patients with early breast
cancer.
The authors wish to thank Dr E. Thurfjell from the Mammography
Screening Unit for kind assistance.
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